{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-003953","form_type":"8-K","ticker":"FEED","cik":"0001326706","company_name":"ENvue Medical, Inc.","filed_at":"2023-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.422850+00:00","generated_at":"2026-06-19T21:33:43.524583+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NanoVibronix effects 1-for-20 reverse stock split, reducing outstanding shares to ~1.64M","bullets":["Reverse split ratio 1-for-20 effective 4:05 p.m. ET on Feb 8, 2023; adjusted trading starts Feb 9.","Outstanding shares reduced from 32,894,359 to approximately 1,644,718, with fractional shares rounded up.","Authorized shares unchanged at 40M; par value remains $0.001 per share.","Proportional adjustments to equity awards, warrants, and convertible securities exercise prices and shares.","Stock symbol remains NAOV; new CUSIP 63008J603."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-003953","json":"https://secwatch.observer/filing/0001493152-23-003953.json","markdown":"https://secwatch.observer/filing/0001493152-23-003953.md","text":"https://secwatch.observer/filing/0001493152-23-003953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223003953/0001493152-23-003953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223003953/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:33:43.524583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27d8830365e47c9317370302a137e07ef8e8ad7e","claim":"ENvue Medical, Inc.: Reverse stock split of common stock at a 1-for-20 ratio via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2023-02-08).","evidence_excerpt":"On February 8, 2023, NanoVibronix, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (Delaware time) on February 8, 2023 (the “Reverse Stock Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223003953/0001493152-23-003953-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-02-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}